Recent Updates
Recently added Catalysts
EVGN Positive Sentiment

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Key Takeaway: Evogene Ltd. will have Chairman Nir Nimrodi participate in a quarterly results call on August 18, 2026, to discuss the situation with dissident shareholders. He will provide insights into the company's perspective and the implications of these developments. The call aims to address shareholder concerns and ensure transparency regarding the company's operations.
Price reaction · baseline $0.651 (2026-08-13 close) · hit after-hours · 1 other EVGN headline(s) in the window, move may be shared
day 0 close
-7.7%
day 1 · peak
-14%
day 3
-7.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Chairman Nir Nimrodi is addressing shareholder concerns directly.
  • The company is transparent about its situation with dissident shareholders.
  • Evogene is focused on innovation in drug development and agricultural products.

CONCERNS & RISKS

  • Dissident shareholders may pose challenges to the company's stability.
  • Potential implications of dissident actions could affect shareholder confidence.

Full Press Release Details

Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET
REHOVOT, Israel , Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN ) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that its Chairman, Nir Nimrodi, will join the Company's upcoming quarterly results conference call on August 18, 2026.
Mr. Nimrodi will address the current situation involving certain dissident shareholders. Mr. Nimrodi will discuss the Company's perspective on these developments and the potential implications of those dissidents' attempted actions for Evogene and its shareholders.
The conference call is scheduled for Tuesday, August 18, 2026, at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the Company's website a few days after the call.
About Evogene:
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AI™ , a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com .

Frequently Asked Questions

When is Evogene's quarterly results call scheduled?

The quarterly results call is scheduled for August 18, 2026, at 9:00 AM ET.

Who will address the dissident shareholders' situation?

Chairman Nir Nimrodi will address the situation involving dissident shareholders.

How can I attend the Evogene conference call?

You can register in advance to attend the conference call online.

What is Evogene's focus in the industry?

Evogene specializes in computational chemistry for drug development and agricultural products.

Last updated: Aug 14, 2026